MedTrace Logo

Doripenem Intrapulmonary Pharmacokinetics in Healthy Adult Subjects

NCT00925392 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-03-14

No results posted yet for this study

Summary

This study is being performed to measure the amount of the antibiotic doripenem (study drug) found in the fluid and cells of the lung and blood after receiving three doses of doripenem. The major objectives of this research are to see how much and for how long doripenem gets into the fluids and cells of the lungs of healthy adult subjects.

Conditions

  • Healthy

Interventions

DRUG

Doripenem

Intravenous 500 mg every (q) 8 hours for 3 doses

DRUG

Doripenem

Intravenous 1000 mg q 8 hours for 3 doses

Sponsors & Collaborators

  • Pulmonary Associates, PA

    collaborator UNKNOWN

  • Keith A. Rodvold

    lead OTHER

Principal Investigators

  • Keith A. Rodvold, Pharm.D. · University of Illinois at Chicago

  • Larry H. Danziger, Pharm.D. · University of Illinois at Chicago

  • Mark H. Gotfried, M.D. · Pulmonary Associates, PA

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00925392 on ClinicalTrials.gov